Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes

Affiliations

• ¹ Université Paris-Cité, INSERM_U1148/LVTS, Paris, France.
• ² Assistance Publique-Hôpitaux de Paris, HôpitalBichat, Paris, France.
• ³ Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
• ⁴ Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, Canada.
• ⁵ St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
• ⁶ Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands.
• ⁷ Netherlands Heart Institute, Utrecht, the Netherlands.
• ⁸ Regeneron Pharmaceuticals, Tarrytown, NY, USA.
• ⁹ IT&M Stats, Neuilly-Sur-Seine, France.
• ¹⁰ Sanofi, Chilly-Mazarin, France.
• ¹¹ Downstate School of Public Health, State University of New York, Brooklyn, NY, USA.
• ¹² CPC Clinical Research and Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA.
• ¹³ Université Paris-Cité, INSERM_U1148/LVTS, Paris, France. [email protected].
• ¹⁴ Assistance Publique-Hôpitaux de Paris, HôpitalBichat, Paris, France. [email protected].
• ¹⁵ Institut Universitaire de France, Paris, France. [email protected].
• ¹⁶ FACT (French Alliance for Cardiovascular Trials), INSERM U-1148, Paris, France. [email protected].
• ¹⁷ Département de Cardiologie, AP-HP Hôpital Bichat, 46 Rue Henri Huchard, Paris, 75018, France. [email protected].